Patents by Inventor James Layne Boucher

James Layne Boucher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
    Patent number: 8691790
    Abstract: A novel etiological hypothesis for Multiple Sclerosis (MS) is proposed describing autoimmune attack of ATP: Cob(I)alamin adenosyltransferase (ATR) thereby inhibiting synthesis of (5?-deoxy-5?-adenosyl)cobamide (referred to as 5?-deoxyadenosylcobalmin or AdoCbl) from Vitamin B 12 providing a basis for therapeutic design and diagnostic methods. Pharmaceutical compositions for therapy of MS, inflammatory neurological diseases and neurodegenerative diseases utilizing AdoCbl, growth hormones, immunomodulators, interleukins, other therapeutic agents, and physiotherapy are also described.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: April 8, 2014
    Inventor: James Layne Boucher
  • Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy
    Publication number: 20110020311
    Abstract: A novel etiological hypothesis for Multiple Sclerosis (MS) is proposed describing autoimmune attack of ATP: Cob (I) alamin adenosyltransferase (ATR) thereby inhibiting synthesis of (5?-deoxy-5?-adenosyl) cobamide (referred to as 5?-deoxyadenosylcobalmin or AdoCbl) from Vitamin B12 providing a basis for therapeutic design and diagnostic methods. Pharmaceutical compositions for therapy of MS, inflammatory neurological diseases and neurodegenerative diseases utilizing AdoCbl, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy are described. Encompassed in embodiments are diagnostic and therapeutic methods based on the amino acid sequence which binds AdoCbl in ATR. A scoping experiment in therapy, parenteral injection of AdoCbl, has been accomplished with a clinically definite MS patient in the Secondary Progressive stage of MS. The dramatic improvement in the patient's condition strongly supports the etiological hypothesis.
    Type: Application
    Filed: July 27, 2009
    Publication date: January 27, 2011
    Inventor: James Layne Boucher